Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739865 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
A Phase 2 study, sponsored by COMPASS Pathways.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT04739865 is a Phase 2 study that has completed, run by COMPASS Pathways. The registered enrollment target is 19 participants.
The verdict
NCT04739865, a Phase 2 study, has completed, sponsored by COMPASS Pathways.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-08-10 |
| Est. Completion | 2021-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04739865
The ClinicalTrials.gov registry entry for NCT04739865 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is COMPASS Pathways, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT04739865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04739865 about?
NCT04739865 is a clinical study titled "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression". The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression
What is the current status of trial NCT04739865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2020-08-10. Estimated completion is 2021-10-14.
What interventions are being tested in trial NCT04739865?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT04739865?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.